Search:
« Cartoon favourites to help sell fruit and veg
Does Your Child Need a Personal Trainer? »

Nastech Submits Investigational New Drug Application For PYY3-36 Nasal Spray To Treat Obesity

Nastech PharmaceuticalCompany Inc. (Nasdaq: NSTK) announced today the submission of anInvestigational New Drug (IND) application to the U.S. Food and DrugAdministration for PYY3-36 (PYY) nasal spray, the company’s leadinvestigational product candidate for treatment of obesity. The filing ofthe IND precedes the initiation of clinical studies in the United States. [click link for full article]

More: continued here

This entry was posted on Monday, June 12th, 2006 at 4:06 am and is filed under Obesity. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.

Leave a Reply
Sign Up for a free account or learn more.
Submit Articles
Member Login
Top Authors
Most Popular Articles
Submission Guidelines
Ezine Notifications
Article RSS Feeds
About Us
Link to Us
Contact Us
Privacy Policy
Terms of Service
Sponsored Links
center>
Resources
Diet Sites
Food Information
Diet Pills
Fitness Resources
Health Help
Women's Links
Men's Links

Powered by Article Dashboard

Related News


  • VIVUS Announces Issuance Of Key Patent For Qnexa(TM) - A Novel Therapy To Treat Obesity
    VIVUS, Inc.(Nasdaq: VVUS), a pharmaceutical company dedicated to the development andcommercialization of novel therapeutic products addressing obesity andsexual health, today announced that the U.S. Patent and Trademark Officehas issued the company's first patent for Qnexa(TM), an investigational,oral treatment for obesity. This patent, number US 7,056,890 B2, broadlycovers the Qnexa product and its use in the treatment of obesity. The termof this patent extends into 2019. [click link for full article]


  • Procedures Beat Meds To Help Patients Fight Obesity, GERD - New Technologies, Safer Options Provide Better Results For GI Disorders
    Upper gastrointestinal surgical procedures to treat conditions like gastroesophageal reflux disease and obesity are becoming popular options, but the medical community still debates the effectiveness and safety of the procedures. [click link for full article]


  • Sanofi wins EU approval to sell anti-obesity drug Acomplia (AFP)
    Parmaceutical group Sanofi-Aventis' logo. Sanofi-Aventis said it had won approval from the European Commission to begin selling its anti-obesity drug Acomplia, which is expected to become the next blockbuster product for the group.(AFP/File)AFP - French pharmaceutical group Sanofi-Aventis said it had won approval from the European Commission to begin selling its anti-obesity drug Acomplia, which is expected to become the next blockbuster product for the group.


  • Herceptin approved for NHS use
    Herceptin, the breast cancer 'wonder drug', should be made available to early-stage sufferers on the NHS, the Government's health watchdog has announced. The move - which will come into effect next month - follows the granting of a UK licence for the drug by European authorities


  • VIVUS Announces Positive Phase 2 Clinical Trial Results With Qnexa, A Novel Therapy To Treat Obesity
    VIVUS, Inc.(Nasdaq: VVUS) today announced positive results from a 200-patient,double-blind, placebo-controlled clinical trial of Qnexa(TM), aninvestigational oral treatment for obesity. In the study conducted by DukeUniversity Medical Center, more than 50% of obese patients in the Qnexatreatment group experienced 10% or more total body weight loss during the24-week study period. Mean weight loss on an intent-to-treat (ITT) basis inthe Qnexa group was 25.1 lbs., compared to 4. [click link for full article]